CLL
MCID: LKM071
MIFTS: 75

Leukemia, Chronic Lymphocytic (CLL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Chronic Lymphocytic

MalaCards integrated aliases for Leukemia, Chronic Lymphocytic:

Name: Leukemia, Chronic Lymphocytic 57 73 37 39
Chronic Lymphocytic Leukemia 12 74 20 36 29 6 42 15 17 71
B-Cell Chronic Lymphocytic Leukemia 12 58 73
Cll 57 12 73
B-Cell Chronic Lymphoid Leukemia 12 58
Chronic Lymphocytic Leukaemia 12 15
Chronic Lymphatic Leukemia 12 73
Lymphoplasmacytic Leukemia 12 71
Small Lymphocytic Lymphoma 58 71
Leukemia, Lymphocytic, Chronic, B-Cell 44
B-Cell Chronic Lymphocytic Leukaemia 12
B Cell Chronic Lymphocytic Leukemia 20
Chronic B-Cell Lymphocytic Leukemia 20
Leukemia, Lymphocytic, Chronic 20
Leukemia Lymphocytic Chronic 54
Leukemia, Chronic Lymphatic 57
Chronic Lymphatic Leukaemia 12
Lymphoplasmacytic Leukaemia 12
Lymphoma Small Lymphocytic 54
Chronic Lymphoid Leukemia 73
B-Cll 58

Characteristics:

Orphanet epidemiological data:

58
b-cell chronic lymphocytic leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
associated with susceptibility loci on chromosome 11p11 (clls1, ), 13q14 (clls2, ), 9q34.1 (clls3, ), 6p25.3 (clls4, ), and 11q24.1 (clls5, )


HPO:

31
leukemia, chronic lymphocytic:
Inheritance somatic mutation autosomal dominant somatic cell mutation


Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:1040
OMIM® 57 151400
KEGG 36 H00005
ICD9CM 34 204.1
MeSH 44 D015451
NCIt 50 C3163
SNOMED-CT 67 51092000
ICD10 32 C91.10
MESH via Orphanet 45 D015451
ICD10 via Orphanet 33 C91.1
UMLS via Orphanet 72 C0023434 C0855095 C1868683
Orphanet 58 ORPHA67038
MedGen 41 C0023434
SNOMED-CT via HPO 68 124975008 277473004 92814006
UMLS 71 C0023434 C0855095 C2854089

Summaries for Leukemia, Chronic Lymphocytic

MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic lymphocytic leukemia (CLL), there are too many lymphocytes, a type of white blood cell. CLL is the second most common type of leukemia in adults. It often occurs during or after middle age and is rare in children. Usually CLL does not cause any symptoms. If you have symptoms, they may include Painless swelling of the lymph nodes in the neck, underarm, stomach, or groin Fatigue Pain or a feeling of fullness below the ribs Fever and infection Weight loss Tests that examine the blood, bone marrow, and lymph nodes diagnose CLL. Your doctor may choose to just monitor you until symptoms appear or change. Treatments include radiation therapy, chemotherapy, surgery to remove the spleen, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary : Leukemia, Chronic Lymphocytic, also known as chronic lymphocytic leukemia, is related to cll/sll and lung cancer, and has symptoms including fatigue, angina pectoris and chest pain. An important gene associated with Leukemia, Chronic Lymphocytic is MIR15A (MicroRNA 15a), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Valganciclovir and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are cellular immunodeficiency and chronic lymphatic leukemia

Disease Ontology : 12 A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

GARD : 20 Chronic lymphocytic leukemia (CLL) is a type of cancer of the white blood cells (lymphocytes). Early signs and symptoms may include swollen lymph nodes, fatigue, weight loss, fever, night sweats and/or frequent infections. CLL usually occurs in adults around the age of 70 and begins in the bone marrow and then spreads to the blood. Over time, CLL may also spread to the lymph nodes and other organs, including the liver, spleen and lungs. The severity and outcome of CLL depends on many factors. The underlying cause is thought to be a combination of genetic and other unknown factors. It usually occurs in people with no family history of the condition, but familial cases have been reported. CLL is diagnosed based on the symptoms and various blood tests. Treatment options depend on many factors, including the stage of the condition, blood cell counts, and whether the CLL has recurred (come back).

OMIM® : 57 Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes in which these cells progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival (summary by Quesada et al., 2012). (151400) (Updated 05-Mar-2021)

KEGG : 36 Chronic lymphocytic leukemia (CLL) is caused by the abnormal progressive accumulation of functionally incompetent monoclonal B-lymphocytes in blood, bone marrow, lymph nodes and spleen. It is the most common adult leukemia in Western countries, accounting for about 30% of total leukaemias. Worldwide there are approximately 180,000 new cases every year. A main focus in CLL research involved the evaluation of genetic features related to somatic gene mutation or deletions that disrupt apoptosis and enhance tumor cell proliferation. The best characterized genes are TP53 (also known as p53) and ATM, for which mutations and/or deletions have been described that predict rapid disease progression, resistance to conventional therapies and poor survival.

UniProtKB/Swiss-Prot : 73 Leukemia, chronic lymphocytic: A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

Wikipedia : 74 Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many... more...

Related Diseases for Leukemia, Chronic Lymphocytic

Diseases in the Leukemia, Chronic Lymphocytic family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 4
Leukemia, Chronic Lymphocytic 5 Adult Acute Lymphocytic Leukemia

Diseases related to Leukemia, Chronic Lymphocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1085)
# Related Disease Score Top Affiliating Genes
1 cll/sll 32.9 TP53 CCND1 ATM
2 lung cancer 32.3 TP53COR1 TP53 MIR424 MIR34A MIR29A MIR16-1
3 renal cell carcinoma, nonpapillary 32.2 TP53 MIR424 MIR34A MIR15A MIR145 MIR143
4 prostate cancer 32.1 TP53COR1 TP53 MIR34A MIR29A MIR16-1 MIR15A
5 b-cell lymphoma 32.1 TP53COR1 TP53 MIR34A CCND1 ATM
6 lymphoma, non-hodgkin, familial 31.9 TP53 MIR424 MIR34A MIR15A MIR143 CCND1
7 mantle cell lymphoma 31.8 TP53 MIR16-1 DLEU2 CCND1 ATM
8 myeloma, multiple 31.8 TP53 MIR181A2 MIR15A MIR145 MIR106B IKZF3
9 diffuse large b-cell lymphoma 31.8 TP53 MIR145 MIR143 CCND1
10 leukemia, acute myeloid 31.6 TP53 MIR424 MIR34A MIR29A MIR181A2 MIR106B
11 kidney cancer 31.6 TP53 MIR424 MIR29A MIR15A MIR106B
12 cervical cancer 31.5 TP53COR1 TP53 MIR34A MIR15A MIR145 MIR143
13 burkitt lymphoma 31.5 TP53COR1 TP53 MIR29A MIR145 MIR143 DLEU1
14 prolymphocytic leukemia 31.5 TP53 CCND1 ATM
15 esophageal cancer 31.5 TP53 MIR34A MIR145 MIR143 MIR107 CCND1
16 larynx cancer 31.5 TP53 MIR34A MIR143 MIR106B DLEU2 CCND1
17 squamous cell carcinoma, head and neck 31.4 TP53 MIR424 MIR15A MIR145 MIR143 CCND1
18 hepatocellular carcinoma 31.4 TP53COR1 TP53 MIR424 MIR34A MIR29A MIR181A2
19 gastric cancer 31.4 TP53COR1 TP53 MIR34A MIR16-1 MIR145 MIR143
20 nervous system disease 31.4 TP53 MIR424 MIR34A MIR29A MIR15A MIR145
21 peripheral nervous system disease 31.3 TP53 MIR424 MIR34A CCND1
22 glioma 31.3 TP53COR1 TP53 POT1 MIR34A MIR181A2 MIR15A
23 hematologic cancer 31.3 MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145
24 oral squamous cell carcinoma 31.3 TP53 MIR34A MIR29A MIR145 MIR143 MIR107
25 rectum cancer 31.3 MIR424 MIR29A MIR145 MIR143
26 central nervous system disease 31.2 MIR34A MIR29A MIR15A MIR145 MIR143 MIR106B
27 melanoma 31.2 TP53 POT1 MIR34A MIR181A2 MIR15A MIR107
28 aortic valve disease 2 31.1 MIR424 MIR34A MIR106B
29 bone marrow cancer 31.0 TP53 MIR34A MIR145 CCND1
30 melanoma, cutaneous malignant 1 31.0 TP53 POT1 CCND1 ATM
31 in situ carcinoma 30.9 TP53 MIR143 CCND1
32 colorectal adenocarcinoma 30.9 TP53 CCND1 ATM
33 clear cell renal cell carcinoma 30.8 TP53 MIR145 MIR106B CCND1
34 leukemia, chronic lymphocytic 2 11.6
35 leukemia, chronic lymphocytic 4 11.6
36 leukemia, chronic lymphocytic 5 11.6
37 leukemia, chronic lymphocytic 1 11.5
38 leukemia, chronic lymphocytic 3 11.5
39 richter's syndrome 11.3
40 pancreatic cancer 11.2 TP53 MIR424 MIR34A MIR181A2 MIR16-1 MIR15A
41 leukemia 11.2
42 immunotactoid glomerulopathy 11.2
43 immunotactoid or fibrillary glomerulopathy 11.2
44 lymphatic system cancer 11.1 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
45 lymphatic system disease 11.1 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
46 respiratory system disease 11.1 TP53 MIR424 MIR34A MIR29A MIR16-1 MIR15A
47 female reproductive system disease 11.0 TP53 MIR424 MIR34A MIR29A MIR15A MIR145
48 intestinal disease 11.0 TP53 MIR424 MIR34A MIR29A MIR15A MIR145
49 cervix disease 11.0 TP53 MIR34A MIR29A MIR15A MIR145 MIR143
50 male reproductive system disease 11.0 MIR424 MIR34A MIR29A MIR15A MIR145 MIR143

Comorbidity relations with Leukemia, Chronic Lymphocytic via Phenotypic Disease Network (PDN): (show all 12)


Acquired Thrombocytopenia Acute Cystitis
Agammaglobulinemia, X-Linked Anemia, Autoimmune Hemolytic
Bronchitis Chronic Leukemia
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Leukemia Neutropenia

Graphical network of the top 20 diseases related to Leukemia, Chronic Lymphocytic:



Diseases related to Leukemia, Chronic Lymphocytic

Symptoms & Phenotypes for Leukemia, Chronic Lymphocytic

Human phenotypes related to Leukemia, Chronic Lymphocytic:

31
# Description HPO Frequency HPO Source Accession
1 cellular immunodeficiency 31 HP:0005374
2 chronic lymphatic leukemia 31 HP:0005550

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Hematology:
chronic lymphatic leukemia

Laboratory Abnormalities:
recurring t(11,14) and t(14,19)(q32,q13.1) translocations

Immunology:
impaired cellular and humoral immunity

Clinical features from OMIM®:

151400 (Updated 05-Mar-2021)

UMLS symptoms related to Leukemia, Chronic Lymphocytic:


fatigue, angina pectoris, chest pain, edema

Drugs & Therapeutics for Leukemia, Chronic Lymphocytic

Drugs for Leukemia, Chronic Lymphocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 427)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Chlorambucil Approved Phase 4 305-03-3 2708
3 Antineoplastic Agents, Hormonal Phase 4
4 Hematinics Phase 4
5 Epoetin alfa Phase 4 113427-24-0
6
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
7
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
8
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
9
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
10
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
11
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
12
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
13
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
14 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
15
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
16
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
19
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
20
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348
21
Ocrelizumab Approved, Investigational Phase 3 637334-45-3
22
Lenograstim Approved, Investigational Phase 3 135968-09-1
23
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
24
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
25
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
26
Tenofovir Experimental, Investigational Phase 3 147127-20-6 464205
27
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
28 Tubulin Modulators Phase 3
29 Antimitotic Agents Phase 3
30
Liposomal doxorubicin Phase 3 31703
31 Ferric Oxide, Saccharated Phase 3
32 Anti-Infective Agents Phase 3
33 Antiviral Agents Phase 3
34 Anti-HIV Agents Phase 3
35 Anti-Retroviral Agents Phase 3
36 Reverse Transcriptase Inhibitors Phase 3
37 Triamcinolone hexacetonide Phase 3
38 triamcinolone acetonide Phase 3
39 Triamcinolone diacetate Phase 3
40 Antibodies, Monoclonal Phase 3
41 Gastrointestinal Agents Phase 3
42 Neurotransmitter Agents Phase 3
43 Antiemetics Phase 3
44 Immunoglobulins, Intravenous Phase 3
45 Hormones Phase 3
46 Protective Agents Phase 3
47 Anti-Inflammatory Agents Phase 3
48 Hormone Antagonists Phase 3
49 Methylprednisolone Acetate Phase 3
50 Neuroprotective Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 1359)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
2 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
3 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
4 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
5 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
6 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
7 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
8 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
9 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
10 Prospective Study of Efficacy and Safety of RFC (Rituximab, Fludarabine, Cyclophosphamide) Regimen as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Favorable Somatic Status Terminated NCT01271010 Phase 4 Cyclophosphamide;Fludarabine;Rituximab
11 Prospective Randomized Study to Compare Efficacy and Safety of RFC-Lite (Rituximab, Fludarabine, Cyclophosphamide) Regimen With LR (Rituximab, Chlorambucil) as a First-Line Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia and Unfavorable Somatic Status Terminated NCT01283386 Phase 4 Chlorambucil;Cyclophosphamide;Fludarabine;Rituximab
12 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
13 Combination of Ibrutinib and As2O3 in the Treatment of CLL Unknown status NCT02757040 Phase 3 Ibrutinib combined with As2O3;ibrutinib
14 Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3 FFP+HDMP+Rituximab
15 A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL Unknown status NCT01678430 Phase 3 Ofatumumab;Chlorambucil;Bendamustine
16 Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients Unknown status NCT01657955 Phase 3 Bendamustine Hydrochloride Injection;Chlorambucil
17 Low Dose Chlorambucil Maintenance Vs. No Treatment Following High-Dose Chlorambucil Induction In Patients With Advanced B-Chronic Lymphocytic Leukemia. A Randomized Phase III Study Of The EORTC LG (CLL-3) Unknown status NCT00017108 Phase 3 chlorambucil;cyclophosphamide;fludarabine phosphate
18 A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia Completed NCT00254163 Phase 3 Fludarabine;Cyclophosphamide;Rituximab;Pentostatin
19 A Phase III Randomized Trial to Evaluate the Efficacy and Safety of Second-Line Therapy With Fludarabine Plus Alemtuzumab vs. Fludarabine Alone in Patients With B-Cell Chronic Lymphocytic Leukemia Completed NCT00086580 Phase 3
20 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial) Completed NCT00774345 Phase 3 Lenalidomide;Placebo
21 A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00046683 Phase 3 alemtuzumab
22 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
23 A Randomized, Open Label Study to Assess the Effect of Maintenance Treatment With Mabthera (Rituximab) Versus No Treatment, After Induction Treatment With Rituximab, Cladribine and Cyclophosphamide (RCC) on Progression-Free Survival in Previously Untreated Patients With Progressive B-Cell Chronic Lymphocytic Leukemia Completed NCT00718549 Phase 3 Cladribine;Cyclophosphamide;Rituximab
24 A Prospective Case Series of Subcutaneous Immunoglobulin for Prophylaxis of Infections in Patients With Chronic Lymphocytic Leukemia With Impaired Humoral Immunity Completed NCT03730129 Phase 2, Phase 3 Hizentra
25 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00769522 Phase 3 Bendamustine;Cyclophosphamide;Fludarabine
26 A Study of IPI-145 and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07 Completed NCT02049515 Phase 3 IPI-145 (duvelisib);Ofatumumab
27 Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT01722487 Phase 3 Ibrutinib;Chlorambucil
28 A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01973387 Phase 3 Rituximab;Ibrutinib
29 Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination With Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01611090 Phase 3 Ibrutinib;Bendamustine hydrochloride;Rituximab;Placebo
30 A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Completed NCT01578707 Phase 3 ofatumumab;ibrutinib
31 A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed NCT02264574 Phase 3 Ibrutinib;Obinutuzumab;Chlorambucil
32 Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia Completed NCT00281918 Phase 3 Rituximab;Cyclophosphamide;Fludarabine Phosphate
33 An Open Label, Multicenter Study Investigating the Safety and Efficacy of Ofatumumab Therapy Versus Physicians' Choice in Patients With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukaemia (CLL) Completed NCT01313689 Phase 3 Ofatumumab;Physicians' Choice
34 Fludarabine Versus Fludarabine Plus Cyclophosphamide in First Line Therapy of Younger Patients (Up to 65 Years) With Advanced Chronic Lymphocytic Leukemia (CLL) Completed NCT00276848 Phase 3 Fludarabine plus Cyclophosphamide;Fludarabine
35 A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) Completed NCT02801578 Phase 2, Phase 3 Ibrutinib
36 Darbepoetin Alfa in Patients With Chronic Lymphocytic Leukemia and Comorbidity Completed NCT00281892 Phase 3 Fludarabine mono
37 Fludarabine Versus Chlorambucil in First Line Therapy of Elderly Patients (More Than 65 Years) With Advanced Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3 Fludarabine;Chlorambucil
38 Open-label, Multicenter, Randomized, Comparative, Phase III Study to Evaluate the Efficacy and Safety of FCR vs. FC Alone in Previously Treated Patients With CD20 Positive B-cell CLL Completed NCT00090051 Phase 3 Rituximab;Fludarabine Phosphate;Cyclophosphamide
39 International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia Completed NCT01118234 Phase 3 Rituximab
40 Prognostic Factors and Risk-Adapted Therapy in Patients With Early Stage Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3 Fludarabine
41 Bendamustine Versus Fludarabine as 2nd-line Treatment in Chronic Lymphocytic Leukemia, Stage BINET B+C / RAI II-IV Completed NCT01423032 Phase 2, Phase 3 bendamustine;Fludarabine
42 Randomized Phase III Trial Comparing Early Treatment With Fludarabine/Cyclophosphamide + Rituximab Versus Deferred Treatment in Untreated Binet Stage A Patients With CLL and High Risk of Progression Completed NCT00275054 Phase 3 Fludarabine;Cyclophosphamide
43 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01539512 Phase 3 Idelalisib;Rituximab;Placebo to match idelalisib
44 A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia Completed NCT01892618 Phase 3 Prevenar 13;Pneumovax
45 Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
46 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia Completed NCT01569295 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo to match idelalisib
47 A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia Completed NCT01905943 Phase 3 Bendamustine;Chlorambucil;Cyclophosphamide;Fludarabine;Obinutuzumab
48 A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) Completed NCT02301156 Phase 3 Ublituximab;ibrutinib
49 A Phase 3 Study to Evaluate the Efficacy and Safety of Dinaciclib or Ofatumumab in Subjects With Refractory Chronic Lymphocytic Leukemia Completed NCT01580228 Phase 3 Dinaciclib;Ofatumumab
50 Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3 cyclophosphamide;fludarabine phosphate

Search NIH Clinical Center for Leukemia, Chronic Lymphocytic

Inferred drug relations via UMLS 71 / NDF-RT 51 :


alemtuzumab
Chlorambucil
Cladribine
Cyclophosphamide
etoposide phosphate
fludarabine
Fludarabine phosphate
Ibrutinib
Ifosfamide
Immunoglobulins, Intravenous
mercaptopurine
pegaspargase
Uracil Mustard

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Lymphocytic cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Genetic Tests for Leukemia, Chronic Lymphocytic

Genetic tests related to Leukemia, Chronic Lymphocytic:

# Genetic test Affiliating Genes
1 Chronic Lymphocytic Leukemia 29

Anatomical Context for Leukemia, Chronic Lymphocytic

MalaCards organs/tissues related to Leukemia, Chronic Lymphocytic:

40
T Cells, Bone Marrow, B Cells, Bone, Myeloid, Spleen, Lymph Node
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Chronic Lymphocytic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Chronic Lymphocytic

Articles related to Leukemia, Chronic Lymphocytic:

(show top 50) (show all 16896)
# Title Authors PMID Year
1
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. 47 61 57
16251535 2005
2
miR-15 and miR-16 induce apoptosis by targeting BCL2. 57 61 47
16166262 2005
3
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. 61 54 57
12595313 2003
4
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. 57 54 61
12724482 2003
5
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. 57 61
23770605 2013
6
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. 61 57
22150006 2011
7
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. 61 57
22158541 2011
8
Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. 57 61
21131588 2011
9
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. 61 54 47
19717645 2009
10
Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. 61 57
17047154 2007
11
HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. 61 57
15931393 2005
12
Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. 57 61
15161669 2004
13
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. 61 57
14973191 2004
14
Cytogenetic findings in familial B-cell chronic lymphocytic leukemia: a report of two cases in a family. 57 61
12781453 2003
15
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. 61 57
12434020 2002
16
Hereditary chronic lymphocytic leukemia: an extended family study and literature review. 57 61
12407690 2002
17
Genomic aberrations and survival in chronic lymphocytic leukemia. 61 57
11136261 2000
18
Linkage analysis for major histocompatibility complex-related genetic susceptibility in familial chronic lymphocytic leukemia. 61 57
11090088 2000
19
Anticipation in familial chronic lymphocytic leukemia. 61 57
10364544 1999
20
Anticipation in familial leukemia. 57 61
8900225 1996
21
Human heavy-chain variable region gene family nonrandomly rearranged in familial chronic lymphocytic leukemia. 61 57
3120193 1987
22
Cloning of the chromosome translocation breakpoint junction of the t(14;19) in chronic lymphocytic leukemia. 57 61
3122218 1987
23
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. 57 61
6610211 1984
24
Familial chronic lymphocytic leukemia. 61 57
6418939 1983
25
Genetic factors predisposing to chronic lymphocytic leukemia and to autoimmune disease. 57 61
7001171 1980
26
Familial chronic lymphocytic leukemia. Immunologic and cellular characterization. 61 57
818930 1976
27
Familial chronic lymphocytic leukemia. 61 57
4184386 1969
28
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. 61 42
33259596 2021
29
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. 42 61
33148933 2020
30
Measurable residual disease in the treatment of chronic lymphocytic leukemia. 61 42
33148932 2020
31
Non-coding recurrent mutations in chronic lymphocytic leukaemia. 57
26200345 2015
32
Mutations driving CLL and their evolution in progression and relapse. 57
26466571 2015
33
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. 57
21642962 2011
34
Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia. 61 47
21130495 2011
35
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression. 61 47
20566844 2010
36
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia. 61 47
20089965 2010
37
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. 61 47
19692702 2009
38
microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. 61 47
19144983 2009
39
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. 61 47
19096009 2009
40
MiR-15a and miR-16-1 cluster functions in human leukemia. 47 61
18362358 2008
41
Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. 61 47
17989717 2008
42
The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. 61 47
17707831 2007
43
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. 47 61
17327404 2007
44
Trinucleotide repeat dynamic mutation identifying susceptibility in familial and sporadic chronic lymphocytic leukaemia. 57
17116127 2007
45
Familial cancer associated with a polymorphism in ARLTS1. 57
15843669 2005
46
Predicting Progression--ZAP-70 in CLL. 57
15329421 2004
47
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. 61 47
15284443 2004
48
MicroRNAs: genomics, biogenesis, mechanism, and function. 57
14744438 2004
49
Molecular diagnosis of the hematologic cancers. 57
12724484 2003
50
A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study. 57
11943260 2002

Variations for Leukemia, Chronic Lymphocytic

ClinVar genetic disease variations for Leukemia, Chronic Lymphocytic:

6 (show top 50) (show all 104)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
2 TP53 NM_000546.5(TP53):c.764T>C (p.Ile255Thr) SNV Likely pathogenic 376623 rs876659675 17:7577517-7577517 17:7674199-7674199
3 HRAS NM_005343.4(HRAS):c.181C>G (p.Gln61Glu) SNV Likely pathogenic 376444 rs28933406 11:533875-533875 11:533875-533875
4 BRAF NM_004333.6(BRAF):c.1803A>C (p.Lys601Asn) SNV Likely pathogenic 376286 rs121913365 7:140453132-140453132 7:140753332-140753332
5 TP53 NM_000546.5(TP53):c.578A>T (p.His193Leu) SNV Likely pathogenic 185822 rs786201838 17:7578271-7578271 17:7674953-7674953
6 TP53 NM_000546.5(TP53):c.584T>G (p.Ile195Ser) SNV Likely pathogenic 376619 rs760043106 17:7578265-7578265 17:7674947-7674947
7 TP53 NM_000546.5(TP53):c.817C>A (p.Arg273Ser) SNV Likely pathogenic 376656 rs121913343 17:7577121-7577121 17:7673803-7673803
8 TP53 NM_000546.5(TP53):c.764T>A (p.Ile255Asn) SNV Likely pathogenic 232289 rs876659675 17:7577517-7577517 17:7674199-7674199
9 BRAF NM_001374258.1(BRAF):c.1900G>A (p.Asp634Asn) SNV Likely pathogenic 44813 rs397516896 7:140453155-140453155 7:140753355-140753355
10 BRAF NM_004333.6(BRAF):c.1780G>C (p.Asp594His) SNV Likely pathogenic 375947 rs397516896 7:140453155-140453155 7:140753355-140753355
11 SF3B2 NM_006842.3(SF3B2):c.2099A>G (p.Glu700Gly) SNV Likely pathogenic 376533 rs1057519960 11:65830884-65830884 11:66063413-66063413
12 TP53 NM_000546.5(TP53):c.332T>G (p.Leu111Arg) SNV Likely pathogenic 376631 rs1057519997 17:7579355-7579355 17:7676037-7676037
13 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
14 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn) SNV Likely pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
15 HRAS NM_005343.4(HRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 376322 rs121913233 11:533874-533874 11:533874-533874
16 TP53 NM_000546.5(TP53):c.577C>T (p.His193Tyr) SNV Likely pathogenic 230256 rs876658468 17:7578272-7578272 17:7674954-7674954
17 TP53 NM_000546.5(TP53):c.742C>G (p.Arg248Gly) SNV Likely pathogenic 376652 rs121912651 17:7577539-7577539 17:7674221-7674221
18 TP53 NM_000546.5(TP53):c.584T>A (p.Ile195Asn) SNV Likely pathogenic 376618 rs760043106 17:7578265-7578265 17:7674947-7674947
19 TP53 NM_000546.5(TP53):c.332T>C (p.Leu111Pro) SNV Likely pathogenic 376630 rs1057519997 17:7579355-7579355 17:7676037-7676037
20 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr) SNV Likely pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
21 PLCG2 NM_002661.5(PLCG2):c.2535A>C (p.Leu845Phe) SNV Likely pathogenic 376214 rs1057519832 16:81962183-81962183 16:81928578-81928578
22 TP53 NM_000546.5(TP53):c.641A>T (p.His214Leu) SNV Likely pathogenic 376616 rs1057519992 17:7578208-7578208 17:7674890-7674890
23 TP53 NM_000546.5(TP53):c.724T>G (p.Cys242Gly) SNV Likely pathogenic 376581 rs1057519982 17:7577557-7577557 17:7674239-7674239
24 TP53 NM_000546.5(TP53):c.841G>C (p.Asp281His) SNV Likely pathogenic 376588 rs764146326 17:7577097-7577097 17:7673779-7673779
25 SF3B1 NM_012433.3(SF3B1):c.1874G>A (p.Arg625His) SNV Likely pathogenic 376534 rs1057519961 2:198267483-198267483 2:197402759-197402759
26 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr) SNV Likely pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
27 SF3B2 NM_006842.3(SF3B2):c.1997A>C (p.His666Pro) SNV Likely pathogenic 376531 rs1057519959 11:65830499-65830499 11:66063028-66063028
28 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 17:7578407-7578407 17:7675089-7675089
29 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His) SNV Likely pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
30 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu) SNV Likely pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
31 PTPN11 NM_002834.4(PTPN11):c.215C>A (p.Ala72Asp) SNV Likely pathogenic 376511 rs121918454 12:112888199-112888199 12:112450395-112450395
32 TP53 NM_000546.5(TP53):c.843C>G (p.Asp281Glu) SNV Likely pathogenic 376587 rs1057519984 17:7577095-7577095 17:7673777-7673777
33 SF3B1 NM_012433.3(SF3B1):c.1873C>T (p.Arg625Cys) SNV Likely pathogenic 376535 rs775623976 2:198267484-198267484 2:197402760-197402760
34 SF3B1 NM_012433.3(SF3B1):c.1996A>G (p.Lys666Glu) SNV Likely pathogenic 376008 rs754688962 2:198267361-198267361 2:197402637-197402637
35 TP53 NM_000546.5(TP53):c.726C>G (p.Cys242Trp) SNV Likely pathogenic 376580 rs375874539 17:7577555-7577555 17:7674237-7674237
36 MYD88 NM_002468.5(MYD88):c.755T>C (p.Leu252Pro) SNV Likely pathogenic 37055 rs387907272 3:38182641-38182641 3:38141150-38141150
37 TP53 NM_000546.5(TP53):c.577C>G (p.His193Asp) SNV Likely pathogenic 376613 rs876658468 17:7578272-7578272 17:7674954-7674954
38 TP53 NM_000546.5(TP53):c.577C>A (p.His193Asn) SNV Likely pathogenic 376614 rs876658468 17:7578272-7578272 17:7674954-7674954
39 HRAS NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 376033 rs121913233 11:533874-533874 11:533874-533874
40 KRAS NM_004985.5(KRAS):c.183A>T (p.Gln61His) SNV Likely pathogenic 45117 rs17851045 12:25380275-25380275 12:25227341-25227341
41 TP53 NM_000546.5(TP53):c.725G>T (p.Cys242Phe) SNV Likely pathogenic 376578 rs121912655 17:7577556-7577556 17:7674238-7674238
42 XPO1 NM_003400.4(XPO1):c.1712A>T (p.Glu571Val) SNV Likely pathogenic 376696 rs1057520010 2:61719471-61719471 2:61492336-61492336
43 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908
44 TP53 NM_000546.5(TP53):c.824G>C (p.Cys275Ser) SNV Likely pathogenic 376583 rs863224451 17:7577114-7577114 17:7673796-7673796
45 XPO1 NM_003400.4(XPO1):c.1712A>C (p.Glu571Ala) SNV Likely pathogenic 376697 rs1057520010 2:61719471-61719471 2:61492336-61492336
46 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro) SNV Likely pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
47 TP53 NM_000546.5(TP53):c.842A>C (p.Asp281Ala) SNV Likely pathogenic 376589 rs587781525 17:7577096-7577096 17:7673778-7673778
48 PLCG2 NM_002661.5(PLCG2):c.2535A>T (p.Leu845Phe) SNV Likely pathogenic 376215 rs1057519832 16:81962183-81962183 16:81928578-81928578
49 TP53 NM_000546.5(TP53):c.796G>C (p.Gly266Arg) SNV Likely pathogenic 376605 rs1057519990 17:7577142-7577142 17:7673824-7673824
50 PTPN11 NM_002834.5(PTPN11):c.214G>A (p.Ala72Thr) SNV Likely pathogenic 177754 rs121918453 12:112888198-112888198 12:112450394-112450394

Copy number variations for Leukemia, Chronic Lymphocytic from CNVD:

7 (show top 50) (show all 1219)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14042 1 103366560 104230405 Loss Chronic lymphocytic leukemia
2 14895 1 110954839 111582296 Loss Chronic lymphocytic leukemia
3 14947 1 111421057 111642223 Loss Chronic lymphocytic leukemia
4 15456 1 115719205 117399077 Loss Chronic lymphocytic leukemia
5 17206 1 141510591 145121245 Deletion Chronic lymphocytic leukemia
6 17207 1 141510591 145121245 Loss Chronic lymphocytic leukemia
7 18527 1 146265358 148164994 Gain Chronic lymphocytic leukemia
8 19758 1 151208615 155645185 Gain Chronic lymphocytic leukemia
9 20025 1 152611898 157344161 Loss Chronic lymphocytic leukemia
10 21378 1 158336749 159355008 Loss Chronic lymphocytic leukemia
11 21384 1 158391645 159433573 Loss Chronic lymphocytic leukemia
12 21385 1 158391645 189498990 Loss Chronic lymphocytic leukemia
13 23023 1 170758115 170759115 Loss Chronic lymphocytic leukemia
14 23030 1 170822660 170823660 Gain Chronic lymphocytic leukemia
15 23626 1 172107770 172108770 Gain Chronic lymphocytic leukemia
16 24171 1 176708253 177307399 Gain Chronic lymphocytic leukemia
17 25274 1 186459864 186720923 Loss Chronic lymphocytic leukemia
18 25359 1 187890295 188217703 Loss Chronic lymphocytic leukemia
19 25435 1 189143434 189363313 Gain Chronic lymphocytic leukemia
20 25473 1 189804292 192389810 Gain Chronic lymphocytic leukemia
21 25685 1 193314169 193528753 Gain Chronic lymphocytic leukemia
22 26789 1 202768030 203457313 Loss Chronic lymphocytic leukemia
23 26818 1 203067017 205298659 Loss Chronic lymphocytic leukemia
24 26975 1 204424298 206588789 Loss Chronic lymphocytic leukemia
25 28076 1 218313329 220732423 Loss Chronic lymphocytic leukemia
26 28130 1 218942571 219164038 Loss Chronic lymphocytic leukemia
27 28133 1 218959043 244561923 Loss Chronic lymphocytic leukemia
28 28265 1 220678511 222112407 Gain Chronic lymphocytic leukemia
29 28321 1 221304071 221582122 Gain Chronic lymphocytic leukemia
30 28577 1 223594083 225234079 Loss Chronic lymphocytic leukemia
31 28643 1 224353010 225571533 Loss Chronic lymphocytic leukemia
32 28702 1 224857883 233411748 Loss Chronic lymphocytic leukemia
33 29066 1 227299711 227518155 Loss Chronic lymphocytic leukemia
34 29113 1 227696842 233631743 Loss Chronic lymphocytic leukemia
35 29265 1 229664393 229947546 Gain Chronic lymphocytic leukemia
36 29501 1 232707626 233302391 Loss Chronic lymphocytic leukemia
37 31053 1 24943712 26054939 Loss Chronic lymphocytic leukemia
38 31193 1 25985121 29490451 Deletion Chronic lymphocytic leukemia
39 31425 1 27504484 28494376 Loss Chronic lymphocytic leukemia
40 32443 1 36783544 38823237 Loss Chronic lymphocytic leukemia
41 33495 1 45606989 46307302 Gain Chronic lymphocytic leukemia
42 34016 1 51545765 53346467 Loss Chronic lymphocytic leukemia
43 34255 1 54029769 55100800 Loss Chronic lymphocytic leukemia
44 34911 1 57712092 58034742 Gain Chronic lymphocytic leukemia
45 35379 1 62697088 63142732 Loss Chronic lymphocytic leukemia
46 35406 1 63335974 63596958 Gain Chronic lymphocytic leukemia
47 35407 1 63335974 63641668 Gain Chronic lymphocytic leukemia
48 36497 1 76364563 76710672 Loss Chronic lymphocytic leukemia
49 36890 1 82341866 82576806 Loss Chronic lymphocytic leukemia
50 36895 1 82581235 82812961 Loss Chronic lymphocytic leukemia

Expression for Leukemia, Chronic Lymphocytic

Search GEO for disease gene expression data for Leukemia, Chronic Lymphocytic.

Pathways for Leukemia, Chronic Lymphocytic

GO Terms for Leukemia, Chronic Lymphocytic

Cellular components related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 MIR424 MIR29A MIR181A2 MIR16-1 MIR15A MIR143
2 extracellular vesicle GO:1903561 9.1 MIR34A MIR29A MIR16-1 MIR15A MIR107 MIR106B

Biological processes related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.97 TP53 MIR29A MIR16-1 MIR15A ATM
2 negative regulation of gene expression GO:0010629 9.91 TP53 MIR34A MIR29A MIR181A2 MIR106B
3 gene silencing by miRNA GO:0035195 9.85 MIR424 MIR34A MIR29A MIR181A2 MIR16-1 MIR15A
4 negative regulation of inflammatory response GO:0050728 9.8 MIR181A2 MIR16-1 MIR15A MIR145
5 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.78 MIR29A MIR16-1 MIR15A
6 negative regulation of protein kinase B signaling GO:0051898 9.77 MIR34A MIR29A MIR145
7 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.76 MIR424 MIR16-1 MIR15A
8 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.72 MIR424 MIR34A MIR15A
9 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.7 TP53 MIR16-1 MIR15A
10 replicative senescence GO:0090399 9.64 TP53 ATM
11 negative regulation of glucose import GO:0046325 9.64 MIR143 MIR107
12 positive regulation of connective tissue replacement GO:1905205 9.63 MIR34A MIR16-1
13 negative regulation of telomerase activity GO:0051974 9.63 TP53 POT1
14 angiotensin-activated signaling pathway GO:0038166 9.62 MIR145 MIR143
15 mitotic G1 DNA damage checkpoint GO:0031571 9.62 TP53 CCND1
16 negative regulation of amyloid precursor protein catabolic process GO:1902992 9.61 MIR29A MIR107
17 negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903588 9.61 MIR424 MIR16-1 MIR15A
18 regulation of telomere maintenance via telomerase GO:0032210 9.59 POT1 ATM
19 negative regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000545 9.57 MIR424 MIR16-1
20 aorta smooth muscle tissue morphogenesis GO:0060414 9.56 MIR145 MIR143
21 negative regulation of vascular endothelial growth factor production GO:1904046 9.56 MIR34A MIR16-1 MIR15A MIR107
22 regulation of phenotypic switching GO:1900239 9.54 MIR145 MIR143
23 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.54 MIR424 MIR34A MIR15A
24 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.5 TP53 MIR34A MIR16-1
25 miRNA mediated inhibition of translation GO:0035278 9.5 MIR29A MIR181A2 MIR16-1 MIR15A MIR145 MIR107
26 negative regulation of endothelial cell chemotaxis to vascular endothelial growth factor GO:1904858 9.48 MIR424 MIR16-1
27 negative regulation of cell chemotaxis to fibroblast growth factor GO:1904848 9.46 MIR16-1 MIR15A
28 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.4 MIR145 MIR143
29 negative regulation of angiogenesis GO:0016525 9.23 MIR424 MIR34A MIR29A MIR16-1 MIR15A MIR145

Molecular functions related to Leukemia, Chronic Lymphocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.65 MIR424 MIR34A MIR29A MIR181A2 MIR16-1 MIR15A
2 histone deacetylase binding GO:0042826 9.33 TP53 IKZF3 CCND1
3 mRNA 3'-UTR binding GO:0003730 9.32 TP53 MIR424 MIR34A MIR29A MIR181A2 MIR16-1

Sources for Leukemia, Chronic Lymphocytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....